# US 2003/0073167 A1 · DNA encoding SNORF36 receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073167 A1
- Document ID: US20030073167A1
- Status: Published application
- Kind: A1
- Application number: 10/146,835
- Filed: 2002-05-16
- Published: 2003-04-17
- Earliest claimed: 1999-05-03
- Assignees: Synaptic Pharmaceutical Corporation
- Inventors: Beth E. Borowsky; Kristine L. Ogozalek; Parul P. Lakhlani; Nika Adham
- Web page: https://patentgrep.com/patent/US20030073167A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 3/12: for electrolyte homeostasis
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/38: of the suprarenal hormones
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/10: for impotence
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/06: Antimigraine agents
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/567: utilising isolate of tissue or organ as binding agent
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2217/075: inducing loss of function, i.e. knock out
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/726: G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention provides isolated nucleic acids encoding mammalian SNORF36 receptors, purified mammalian SNORF36 receptors, vectors comprising nucleic acid encoding mammalian SNORF36 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF36 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF36 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF36 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF36 receptors, methods of isolating mammalian SNORF36 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF36 receptors, as well as methods of determining binding of compounds to mammalian SNORF36 receptors, methods of identifying agonists and antagonists of SNORF36 receptors, and agonists and antagonists so identified.

## Claims

### Claim 1

An isolated nucleic acid encoding a mammalian SNORF36 receptor.

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid is DNA.

### Claim 3 (depends on 2)

The DNA of claim 2, wherein the DNA is cDNA.

### Claim 4 (depends on 2)

The DNA of claim 2, wherein the DNA is genomic DNA.

### Claim 5 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid is RNA.

### Claim 6 (depends on 1)

The nucleic acid of claim 1, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor.

### Claim 7 (depends on 1)

The nucleic acid of claim 1, wherein the mammalian SNORF36 receptor is a human SNORF36b receptor.

### Claim 8 (depends on 6)

The nucleic acid of claim 6, wherein the human SNORF36a receptor has an amino acid sequence identical to that encoded by the plasmid pcDNA3.1-hSNORF36a-f (ATCC Accession No. PTA-203977).

### Claim 9 (depends on 7)

The nucleic acid of claim 7, wherein the human SNORF36b receptor has an amino acid sequence identical to that encoded by the plasmid pcDNA3.1-hSNORF36b-f (ATCC Accession No. PTA-203976).

### Claim 10 (depends on 1)

The nucleic acid of claim 1, wherein the mammalian SNORF36 receptor is a rat SNORF36 receptor.

### Claim 11 (depends on 10)

The nucleic acid of claim 10, wherein the rat SNORF36 receptor has an amino acid sequence identical to that encoded by the plasmid pEXJ.T7-rSNORF36-f (ATCC Patent Depository No. PTA-1216).

### Claim 12 (depends on 6)

The nucleic acid of claim 6, wherein the human SNORF36a receptor has an amino acid sequence identical to the amino acid sequence shown in FIGS. 2A-2B (SEQ ID NO: 2).

### Claim 13 (depends on 7)

The nucleic acid of claim 7, wherein the human SNORF36b receptor has an amino acid sequence identical to the amino acid sequence shown in FIGS. 4A-4C (SEQ ID NO: 4).

### Claim 14 (depends on 10)

The nucleic acid of claim 10, wherein the rat SNORF36 receptor has an amino acid sequence identical to the amino acid sequence shown in FIGS. 10A-10C. (SEQ ID NO: 8).

### Claim 15

A purified mammalian SNORF36 receptor protein.

### Claim 16 (depends on 15)

The purified mammalian SNORF36 receptor protein of claim 15, wherein the SNORF36 receptor protein is a human SNORF36a receptor protein.

### Claim 17 (depends on 15)

The purified mammalian SNORF36 receptor protein of claim 15, wherein the SNORF36 receptor protein is a human SNORF36b receptor protein.

### Claim 18 (depends on 15)

The purified mammalian SNORF36 receptor protein of claim 15, wherein the SNORF36 receptor protein is a rat SNORF36 receptor protein.

### Claim 19 (depends on 1)

A vector comprising the nucleic acid of claim 1.

### Claim 20 (depends on 6, 7)

A vector comprising the nucleic acid of claim 6 or claim 7.

### Claim 21 (depends on 10)

A vector comprising the nucleic acid of claim 10.

### Claim 22 (depends on 19, 20, 21)

A vector of claim 19, 20 or 21 adapted for expression in a cell which comprises the regulatory elements necessary for expression of the nucleic acid in the cell operatively linked to the nucleic acid encoding the receptor so as to permit expression thereof, wherein the cell is a bacterial, amphibian, yeast, insect or mammalian cell.

### Claim 23 (depends on 22)

The vector of claim 22, wherein the vector is a baculovirus.

### Claim 24 (depends on 19)

The vector of claim 19, wherein the vector is a plasmid.

### Claim 25 (depends on 24)

The plasmid of claim 24 designated pcDNA3.1-hSNORF36a-f (ATCC Accession No. PTA-203977).

### Claim 26 (depends on 24)

The plasmid of claim 24 designated pcDNA3.1-hSNORF36b-f (ATCC Accession No. PTA-203976).

### Claim 27 (depends on 24)

The plasmid of claim 24 designated pEXJ.T7-rSNORF36-f (ATCC Patent Depository No. PTA-1216).

### Claim 28 (depends on 22)

A cell comprising the vector of claim 22.

### Claim 29 (depends on 28)

A cell of claim 28, wherein the cell is a non-mammalian cell.

### Claim 30 (depends on 29)

A cell of claim 29, wherein the non-mammalian cell is a Xenopus oocyte cell or a Xenopus melanophore cell.

### Claim 31 (depends on 28)

A cell of claim 28, wherein the cell is a mammalian cell.

### Claim 32 (depends on 31)

A mammalian cell of claim 31, wherein the cell is a COS-7 cell, a 293 human embryonic kidney cell, a NIH-3T3 cell, a LM(tk−) cell, a mouse Y1 cell, or a CHO cell.

### Claim 33 (depends on 28)

A cell of claim 28, wherein the cell is an insect cell.

### Claim 34 (depends on 33)

An insect cell of claim 33, wherein the insect cell is an Sf9 cell, an Sf21 cell or a Trichoplusia ni 5B-4 cell.

### Claim 35 (depends on 28, 29, 31, 32, 33, 34)

A membrane preparation isolated from the cell of any one of claims 28, 29, 31, 32, 33 or 34.

### Claim 36

A nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian SNORF36 receptor, wherein the probe has a sequence complementary to a unique sequence present within one of the two strands of the nucleic acid encoding the human SNORF36a receptor contained in plasmid pcDNA3.1-hSNORF36a-f (ATCC Accession No. PTA-203977).

### Claim 37

A nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian SNORF36 receptor, wherein the probe has a sequence complementary to a unique sequence present within one of the two strands of the nucleic acid encoding the human SNORF36b receptor contained in plasmid pcDNA3.1-hSNORF36b-f (ATCC Accession No. PTA-203976).

### Claim 38

A nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian SNORF36 receptor, wherein the probe has a sequence complementary to a unique sequence present within one of the two strands of the nucleic acid encoding the mammalian SNORF36 receptor contained in plasmid pEXJ.T7-rSNORF36-f (ATCC Patent Depository No. PTA-1216).

### Claim 39

A nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian SNORF36 receptor, wherein the probe has a sequence complementary to a unique sequence present within (a) the nucleic acid sequence shown in FIGS. 1A-1C (SEQ ID NO: 1) or (b) the reverse complement thereof.

### Claim 40

A nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian SNORF36 receptor, wherein the probe has a sequence complementary to a unique sequence present within (a) the nucleic acid sequence shown in FIGS. 3A-3C (SEQ ID NO: 3) or (b) the reverse complement thereof.

### Claim 41

A nucleic acid probe comprising at least 15 nucleotides, which probe specifically hybridizes with a nucleic acid encoding a mammalian SNORF36 receptor, wherein the probe has a sequence complementary to a unique sequence present within (a) the nucleic acid sequence shown in FIGS. 9A-9C (SEQ ID NO: 7) or (b) the reverse complement thereof.

### Claim 42 (depends on 39, 40, 41)

The nucleic acid probe of claim 39, 40 or 41, wherein the nucleic acid is DNA.

### Claim 43 (depends on 39, 40, 41)

The nucleic acid probe of claim 39, 40 or 41, wherein the nucleic acid is RNA.

### Claim 44 (depends on 5)

An antisense oligonucleotide having a sequence capable of specifically hybridizing to the RNA of claim 5, so as to prevent translation of the RNA.

### Claim 45 (depends on 4)

An antisense oligonucleotide having a sequence capable of specifically hybridizing to the genomic DNA of claim 4, so as to prevent transcription of the genomic DNA.

### Claim 46 (depends on 44, 45)

An antisense oligonucleotide of claim 44 or 45, wherein the oligonucleotide comprises chemically modified nucleotides or nucleotide analogues.

### Claim 47 (depends on 1)

An antibody capable of binding to a mammalian SNORF36 receptor encoded by the nucleic acid of claim 1.

### Claim 48 (depends on 47)

An antibody of claim 47, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.

### Claim 49 (depends on 47)

An agent capable of competitively inhibiting the binding of the antibody of claim 47 to a mammalian SNORF36 receptor.

### Claim 50 (depends on 47)

An antibody of claim 47, wherein the antibody is a monoclonal antibody or antisera.

### Claim 51 (depends on 44)

A pharmaceutical composition comprising (a) an amount of the oligonucleotide of claim 44 capable of passing through a cell membrane and effective to reduce expression of a mammalian SNORF36 receptor and (b) a pharmaceutically acceptable carrier capable of passing through the cell membrane.

### Claim 52 (depends on 51)

A pharmaceutical composition of claim 51, wherein the oligonucleotide is coupled to a substance which inactivates mRNA.

### Claim 53 (depends on 52)

A pharmaceutical composition of claim 52, wherein the substance which inactivates mRNA is a ribozyme.

### Claim 54 (depends on 52)

A pharmaceutical composition of claim 52, wherein the pharmaceutically acceptable carrier comprises a structure which binds to a mammalian SNORF36 receptor on a cell capable of being taken up by the cells after binding to the structure.

### Claim 55 (depends on 54)

A pharmaceutical composition of claim 54, wherein the pharmaceutically acceptable carrier is capable of binding to a mammalian SNORF36 receptor which is specific for a selected cell type.

### Claim 56 (depends on 47)

A pharmaceutical composition which comprises an amount of the antibody of claim 47 effective to block binding of a ligand to a human SNORF36 receptor and a pharmaceutically acceptable carrier.

### Claim 57 (depends on 1)

A transgenic, nonhuman mammal expressing DNA encoding a mammalian SNORF36 receptor of claim 1.

### Claim 58

A transgenic, nonhuman mammal comprising a homologous recombination knockout of the native mammalian SNORF36 receptor.

### Claim 59 (depends on 1)

A transgenic, nonhuman mammal whose genome comprises antisense DNA complementary to the DNA encoding a mammalian SNORF36 receptor of claim 1 so placed within the genome as to be transcribed into antisense mRNA which is complementary to and hybridizes with mRNA encoding the mammalian SNORF36 receptor so as to thereby reduce translation of such mRNA and expression of such receptor.

### Claim 60 (depends on 57, 58)

The transgenic, nonhuman mammal of claim 57 or 58, wherein the DNA encoding the mammalian SNORF36 receptor additionally comprises an inducible promoter.

### Claim 61 (depends on 57, 58)

The transgenic, nonhuman mammal of claim 57 or 58, wherein the DNA encoding the mammalian SNORF36 receptor additionally comprises tissue specific regulatory elements.

### Claim 62 (depends on 57, 58)

A transgenic, nonhuman mammal of claim 57, 58, or 59, wherein the transgenic, nonhuman mammal is a mouse.

### Claim 63

A process for identifying a chemical compound which specifically binds to a mammalian SNORF36 receptor which comprises contacting cells containing DNA encoding, and expressing on their cell surface, the mammalian SNORF36 receptor, wherein such cells do not normally express the mammalian SNORF36 receptor, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian SNORF36 receptor.

### Claim 64

A process for identifying a chemical compound which specifically binds to a mammalian SNORF36 receptor which comprises contacting a membrane preparation from cells containing DNA encoding, and expressing on their cell surface, the mammalian SNORF36 receptor, wherein such cells do not normally express the mammalian SNORF36 receptor, with the compound under conditions suitable for binding, and detecting specific binding of the chemical compound to the mammalian SNORF36 receptor.

### Claim 65 (depends on 63, 64)

The process of claim 63 or 64, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor or a human SNORF36b receptor.

### Claim 66 (depends on 63, 64)

The process of claim 63 or 64, wherein the mammalian SNORF36 receptor has substantially the same amino acid sequence as the human SNORF36a receptor encoded by plasmid pcDNA3.1-hSNORF36a-f (ATCC Accession No. PTA-203977).

### Claim 67 (depends on 63, 64)

The process of claim 63 or 64, wherein the mammalian SNORF36 receptor has substantially the same amino acid sequence as the human SNORF36b receptor encoded by the plasmid pcDNA3.1-hSNORF36b-f (ATCC Accession No. PTA-203976).

### Claim 68 (depends on 63, 64)

The process of claim 63 or 64, wherein the mammalian SNORF36 receptor has substantially the same amino acid sequence as that shown in FIGS. 2A-2B (SEQ ID NO: 2) or FIGS. 4A-4C (SEQ ID NO: 4).

### Claim 69 (depends on 63, 64)

The process of claim 63 or 64, wherein the mammalian SNORF36 receptor has the amino acid sequence shown in FIGS. 2A-2B (SEQ ID NO: 2) or FIGS. 4A-4C (SEQ ID NO: 4).

### Claim 70 (depends on 63, 64)

The process of claim 63 or 64, wherein the mammalian SNORF36 receptor is a rat SNORF36 receptor.

### Claim 71 (depends on 63, 64)

The process of claim 63 or 64, wherein the mammalian SNORF36 receptor has substantially the same amino acid sequence as the rat SNORF36 receptor encoded by plasmid pEXJ.T7-rSNORF36-f (ATCC Patent Depository No. PTA-1216).

### Claim 72 (depends on 63, 64)

The process of claim 63 or 64, wherein the mammalian SNORF36 receptor has substantially the same amino acid sequence as that shown in FIGS. 10A-10C. (SEQ ID NO: 8).

### Claim 73 (depends on 63, 64)

The process of claim 63 or 64, wherein the mammalian SNORF36 receptor has the same amino acid sequence as that shown in FIGS. 10A-10C. (SEQ ID NO: 8).

### Claim 74 (depends on 63, 64)

The process of claim 63 or 64, wherein the compound is not previously known to bind to a mammalian SNORF36 receptor.

### Claim 75 (depends on 74)

A compound identified by the process of claim 74.

### Claim 76 (depends on 63, 64)

A process of claim 63 or 64, wherein the cell is an insect cell.

### Claim 77 (depends on 63, 64)

The process of claim 63 or 64, wherein the cell is a mammalian cell.

### Claim 78 (depends on 77)

The process of claim 77, wherein the cell is nonneuronal in origin.

### Claim 79 (depends on 78)

The process of claim 78, wherein the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell, a mouse Y1 cell, or a LM(tk−) cell.

### Claim 80 (depends on 77)

A process of claim 77, wherein the compound is a compound not previously known to bind to a mammalian SNORF36 receptor.

### Claim 81 (depends on 80)

A compound identified by the process of claim 80.

### Claim 82

A process involving competitive binding for identifying a chemical compound which specifically binds to a mammalian SNORF36 receptor which comprises separately contacting cells expressing on their cell surface the mammalian SNORF36 receptor, wherein such cells do not normally express the mammalian SNORF36 receptor, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second chemical compound, under conditions suitable for binding of such compounds to the receptor, and detecting specific binding of the chemical compound to the mammalian SNORF36 receptor, a decrease in the binding of the second chemical compound to the mammalian SNORF36 receptor in the presence of the chemical compound being tested indicating that such chemical compound binds to the mammalian SNORF36 receptor.

### Claim 83

A process involving competitive binding for identifying a chemical compound which specifically binds to a mammalian SNORF36 receptor which comprises separately contacting a membrane preparation from cells expressing on their cell surface the mammalian SNORF36 receptor, wherein such cells do not normally express the mammalian SNORF36 receptor, with both the chemical compound and a second chemical compound known to bind to the receptor, and with only the second chemical compound, under conditions suitable for binding of such compounds to the receptor, and detecting specific binding of the chemical compound to the mammalian SNORF36 receptor, a decrease in the binding of the second chemical compound to the mammalian SNORF36 receptor in the presence of the chemical compound being tested indicating that such chemical compound binds to the mammalian SNORF36 receptor.

### Claim 84 (depends on 82, 83)

A process of claim 82 or 83, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor or a human SNORF36b receptor.

### Claim 85 (depends on 82, 83)

A process of claim 82 or 83, wherein the mammalian SNORF36 receptor is a rat SNORF36 receptor.

### Claim 86 (depends on 82, 83)

The process of claim 82 or 83, wherein the cell is an insect cell.

### Claim 87 (depends on 82, 83)

The process of claim 82 or 83, wherein the cell is a mammalian cell.

### Claim 88 (depends on 87)

The process of claim 87, wherein the cell is nonneuronal in origin.

### Claim 89 (depends on 88)

The process of claim 88, wherein the nonneuronal cell is a COS-7 cell, 293 human embryonic kidney cell, a CHO cell, a NIH-3T3 cell, a mouse Y1 cell, or a LM(tk−) cell.

### Claim 90 (depends on 89)

The process of claim 89, wherein the compound is not previously known to bind to a mammalian SNORF36 receptor.

### Claim 91 (depends on 90)

A compound identified by the process of claim 90.

### Claim 92

A method of screening a plurality of chemical compounds not known to bind to a mammalian SNORF36 receptor to identify a compound which specifically binds to the mammalian SNORF36 receptor, which comprises
(a) contacting cells transfected with, and expressing, DNA encoding the mammalian SNORF36 receptor with a compound known to bind specifically to the mammalian SNORF36 receptor;
(b) contacting the cells of step (a) with the plurality of compounds not known to bind specifically to the mammalian SNORF36 receptor, under conditions permitting binding of compounds known to bind to the mammalian SNORF36 receptor;
(c) determining whether the binding of the compound known to bind to the mammalian SNORF36 receptor is reduced in the presence of the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so
(d) separately determining the binding to the mammalian SNORF36 receptor of each compound included in the plurality of compounds, so as to thereby identify any compound included therein which specifically binds to the mammalian SNORF36 receptor.

### Claim 93

A method of screening a plurality of chemical compounds not known to bind to a mammalian SNORF36 receptor to identify a compound which specifically binds to the mammalian SNORF36 receptor, which comprises
(a) contacting a membrane preparation from cells transfected with, and expressing, DNA encoding the mammalian SNORF36 receptor with the plurality of compounds not known to bind specifically to the mammalian SNORF36 receptor under conditions permitting binding of compounds known to bind to the mammalian SNORF36 receptor;
(b) determining whether the binding of a compound known to bind to the mammalian SNORF36 receptor is reduced in the presence of the plurality of compounds, relative to the binding of the compound in the absence of the plurality of compounds; and if so
(c) separately determining the binding to the mammalian SNORF36 receptor of each compound included in the plurality of compounds, so as to thereby identify any compound included therein which specifically binds to the mammalian SNORF36 receptor.

### Claim 94 (depends on 92, 93)

A method of claim 92 or 93, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor or a human SNORF36b receptor.

### Claim 95 (depends on 92, 93)

A method of claim 92 or 93, wherein the mammalian SNORF36 receptor is a rat SNORF36 receptor.

### Claim 96 (depends on 92, 93)

A method of claim 92 or 93, wherein the cell is a mammalian cell.

### Claim 97 (depends on 96)

A method of claim 96, wherein the mammalian cell is non-neuronal in origin.

### Claim 98 (depends on 97)

The method of claim 97, wherein the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, a LM(tk−) cell, a CHO cell, a mouse Y1 cell, or an NIH-3T3 cell.

### Claim 99 (depends on 36, 37, 38, 39, 40, 41)

A method of detecting expression of a mammalian SNORF36 receptor by detecting the presence of mRNA coding for the mammalian SNORF36 receptor which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with the nucleic acid probe of claim 36, 37, 38, 39, 40 or 41 under hybridizing conditions, detecting the presence of mRNA hybridized to the probe, and thereby detecting the expression of the mammalian SNORF36 receptor by the cell.

### Claim 100 (depends on 47)

A method of detecting the presence of a mammalian SNORF36 receptor on the surface of a cell which comprises contacting the cell with the antibody of claim 47 under conditions permitting binding of the antibody to the receptor, detecting the presence of the antibody bound to the cell, and thereby detecting the presence of the mammalian SNORF36 receptor on the surface of the cell.

### Claim 101 (depends on 57)

A method of determining the physiological effects of varying levels of activity of mammalian SNORF36 receptors which comprises producing a transgenic, nonhuman mammal of claim 57 whose levels of mammalian SNORF36 receptor activity are varied by use of an inducible promoter which regulates mammalian SNORF36 receptor expression.

### Claim 102 (depends on 57)

A method of determining the physiological effects of varying levels of activity of mammalian SNORF36 receptors which comprises producing a panel of transgenic, nonhuman mammals of claim 57 each expressing a different amount of mammalian SNORF36 receptor.

### Claim 103 (depends on 57, 58)

A method for identifying an antagonist capable of alleviating an abnormality wherein the abnormality is alleviated by decreasing the activity of a mammalian SNORF36 receptor comprising administering a compound to the transgenic, nonhuman mammal of claim 57, 58, or 59, and determining whether the compound alleviates any physiological and/or behavioral abnormality displayed by the transgenic, nonhuman mammal as a result of overactivity of a mammalian SNORF36 receptor, the alleviation of such an abnormality identifying the compound as an antagonist.

### Claim 104 (depends on 103)

The method of claim 103, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.

### Claim 105 (depends on 103)

An antagonist identified by the method of claim 103.

### Claim 106 (depends on 105)

A composition comprising an antagonist of claim 105 and a carrier.

### Claim 107 (depends on 106)

A method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a mammalian SNORF36 receptor which comprises administering to the subject an effective amount of the pharmaceutical composition of claim 106, thereby treating the abnormality.

### Claim 108 (depends on 57, 58)

A method for identifying an agonist capable of alleviating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a mammalian SNORF36 receptor comprising administering a compound to the transgenic, nonhuman mammal of claim 57, 58, or 59, and determining whether the compound alleviates any physiological and/or behavioral abnormality displayed by the transgenic, nonhuman mammal, the alleviation of such an abnormality identifying the compound as an agonist.

### Claim 109 (depends on 108)

The method of claim 108, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.

### Claim 110 (depends on 109)

An agonist identified by the method of claim 109.

### Claim 111 (depends on 110)

A composition comprising an agonist identified by the method of claim 110 and a carrier.

### Claim 112 (depends on 111)

A method of treating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a mammalian SNORF36 receptor which comprises administering to the subject an effective amount of the composition of claim 111 so as to thereby treat the abnormality.

### Claim 113 (depends on 1)

A method for diagnosing a predisposition to a disorder associated with the activity of a specific mammalian allele which comprises:
(a) obtaining DNA of subjects suffering from the disorder;
(b) performing a restriction digest of the DNA with a panel of restriction enzymes;
(c) electrophoretically separating the resulting DNA fragments on a sizing gel;
(d) contacting the resulting gel with a nucleic acid probe capable of specifically hybridizing with a unique sequence included within the sequence of a nucleic acid molecule encoding a mammalian SNORF36 receptor and labeled with a detectable marker;
(e) detecting labeled bands which have hybridized to the DNA encoding a mammalian SNORF36 receptor of claim 1 to create a unique band pattern specific to the DNA of subjects suffering from the disorder;
(f) repeating steps (a)-(e) with DNA obtained for diagnosis from subjects not yet suffering from the disorder; and
(g) comparing the unique band pattern specific to the DNA of subjects suffering from the disorder from step (e) with the band pattern from step (f) for subjects not yet suffering from the disorder so as to determine whether the patterns are the same or different and thereby diagnose predisposition to the disorder if the patterns are the same.

### Claim 114 (depends on 113)

The method of claim 113, wherein a disorder associated with the activity of a specific mammalian allele is diagnosed.

### Claim 115 (depends on 15)

A method of preparing the purified mammalian SNORF36 receptor of claim 15 which comprises:
(a) culturing cells which express the mammalian SNORF36 receptor;
(b) recovering the mammalian SNORF36 receptor from the cells; and
(c) purifying the mammalian SNORF36 receptor so recovered.

### Claim 116 (depends on 15)

A method of preparing the purified mammalian SNORF36 receptor of claim 15 which comprises:
(a) inserting a nucleic acid encoding the mammalian SNORF36 receptor into a suitable expression vector;
(b) introducing the resulting vector into a suitable host cell;
(c) placing the resulting host cell in suitable conditions permitting the production of the mammalian SNORF36 receptor;
(d) recovering the mammalian SNORF36 receptor so produced; and optionally
(e) isolating and/or purifying the mammalian SNORF36 receptor so recovered.

### Claim 117

A process for determining whether a chemical compound is a mammalian SNORF36 receptor agonist which comprises contacting cells transfected with and expressing DNA encoding the mammalian SNORF36 receptor with the compound under conditions permitting the activation of the mammalian SNORF36 receptor, and detecting any increase in mammalian SNORF36 receptor activity, so as to thereby determine whether the compound is a mammalian SNORF36 receptor agonist.

### Claim 118

A process for determining whether a chemical compound is a mammalian SNORF36 receptor antagonist which comprises contacting cells transfected with and expressing DNA encoding the mammalian SNORF36 receptor with the compound in the presence of a known mammalian SNORF36 receptor agonist, under conditions permitting the activation of the mammalian SNORF36 receptor, and detecting any decrease in mammalian SNORF36 receptor activity, so as to thereby determine whether the compound is a mammalian SNORF36 receptor antagonist.

### Claim 119 (depends on 117, 118)

A process of claim 117 or 118, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.

### Claim 120 (depends on 117)

A composition which comprises an amount of a mammalian SNORF36 receptor agonist determined by the process of claim 117 effective to increase activity of a mammalian SNORF36 receptor and a carrier.

### Claim 121 (depends on 120)

A composition of claim 120, wherein the mammalian SNORF36 receptor agonist is not previously known.

### Claim 122 (depends on 118)

A composition which comprises an amount of a mammalian SNORF36 receptor antagonist determined by the process of claim 118 effective to reduce activity of a mammalian SNORF36 receptor and a carrier.

### Claim 123 (depends on 122)

A composition of claim 122, wherein the mammalian SNORF36 receptor antagonist is not previously known.

### Claim 124

A process for determining whether a chemical compound specifically binds to and activates a mammalian SNORF36 receptor, which comprises contacting cells producing a second messenger response and expressing on their cell surface the mammalian SNORF36 receptor, wherein such cells do not normally express the mammalian SNORF36 receptor, with the chemical compound under conditions suitable for activation of the mammalian SNORF36 receptor, and measuring the second messenger response in the presence and in the absence of the chemical compound, a change in the second messenger response in the presence of the chemical compound indicating that the compound activates the mammalian SNORF36 receptor.

### Claim 125 (depends on 124)

The process of claim 124, wherein the second messenger response comprises chloride channel activation and the change in second messenger is an increase in the level of chloride current.

### Claim 126 (depends on 124)

The process of claim 124, wherein the second messenger response comprises intracellular calcium levels and the change in second messenger is an increase in the measure of intracellular calcium.

### Claim 127 (depends on 124)

The process of claim 124, wherein the second messenger response comprises release of inositol phosphate and the change in second messenger is an increase in the level of inositol phosphate.

### Claim 128

A process for determining whether a chemical compound specifically binds to and inhibits activation of a mammalian SNORF36 receptor, which comprises separately contacting cells producing a second messenger response and expressing on their cell surface the mammalian SNORF36 receptor, wherein such cells do not normally express the mammalian SNORF36 receptor, with both the chemical compound and a second chemical compound known to activate the mammalian SNORF36 receptor, and with only the second chemical compound, under conditions suitable for activation of the mammalian SNORF36 receptor, and measuring the second messenger response in the presence of only the second chemical compound and in the presence of both the second chemical compound and the chemical compound, a smaller change in the second messenger response in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound indicating that the chemical compound inhibits activation of the mammalian SNORF36 receptor.

### Claim 129 (depends on 128)

The process of claim 128, wherein the second messenger response comprises chloride channel activation and the change in second messenger response is a smaller increase in the level of chloride current in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound.

### Claim 130 (depends on 129)

The process of claim 129, wherein the second messenger response comprises change in intracellular calcium levels and the change in second messenger response is a smaller increase in the measure of intracellular calcium in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound.

### Claim 131 (depends on 128)

The process of claim 128, wherein the second messenger response comprises release of inositol phosphate and the change in second messenger response is a smaller increase in the level of inositol phosphate in the presence of both the chemical compound and the second chemical compound than in the presence of only the second chemical compound.

### Claim 132 (depends on 124, 125, 126, 127, 128, 129, 130)

A process of any of claims 124, 125, 126, 127, 128, 129, 130, or 131, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.

### Claim 133 (depends on 121, 125, 126, 127, 128, 129, 130)

The process of any one of claims 121, 125, 126, 127, 128, 129, 130, or 131, wherein the cell is an insect cell.

### Claim 134 (depends on 124, 125, 126, 127, 128, 129, 130)

The process of any one of claims 124, 125, 126, 127, 128, 129, 130, or 131, wherein the cell is a mammalian cell.

### Claim 135 (depends on 134)

The process of claim 134, wherein the mammalian cell is nonneuronal in origin.

### Claim 136 (depends on 135)

The process of claim 135, wherein the nonneuronal cell is a COS-7 cell, CHO cell, 293 human embryonic kidney cell, NIH-3T3 cell or LM(tk−) cell.

### Claim 137 (depends on 124, 125, 126, 127, 128, 129, 130)

The process of claim 124, 125, 126, 127, 128, 129, 130, or 131, wherein the compound is not previously known to bind to a mammalian SNORF36 receptor.

### Claim 138 (depends on 137)

A compound determined by the process of claim 137.

### Claim 139 (depends on 124, 125, 126)

A composition which comprises an amount of a mammalian SNORF36 receptor agonist determined to be such by the process of claim 124, 125, 126, or 127, effective to increase activity of the mammalian SNORF36 receptor and a carrier.

### Claim 140 (depends on 139)

A composition of claim 139, wherein the mammalian SNORF36 receptor agonist is not previously known.

### Claim 141 (depends on 128, 129, 130)

A composition which comprises an amount of a mammalian SNORF36 receptor antagonist determined to be such by the process of claim 128, 129, 130, or 131, effective to reduce activity of the mammalian SNORF36 receptor and a carrier.

### Claim 142 (depends on 141)

A composition of claim 141, wherein the mammalian SNORF36 receptor antagonist is not previously known.

### Claim 143

A method of screening a plurality of chemical compounds not known to activate a mammalian SNORF36 receptor to identify a compound which activates the mammalian SNORF36 receptor which comprises:
(a) contacting cells transfected with and expressing the mammalian SNORF36 receptor with the plurality of compounds not known to activate the mammalian SNORF36 receptor, under conditions permitting activation of the mammalian SNORF36 receptor;
(b) determining whether the activity of the mammalian SNORF36 receptor is increased in the presence of one or more of the compounds; and if so
(c) separately determining whether the activation of the mammalian SNORF36 receptor is increased by any compound included in the plurality of compounds, so as to thereby identify each compound which activates the mammalian SNORF36 receptor.

### Claim 144 (depends on 143)

A method of claim 143, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.

### Claim 145

A method of screening a plurality of chemical compounds not known to inhibit the activation of a mammalian SNORF36 receptor to identify a compound which inhibits the activation of the mammalian SNORF36 receptor, which comprises:
(a) contacting cells transfected with and expressing the mammalian SNORF36 receptor with the plurality of compounds in the presence of a known mammalian SNORF36 receptor agonist, under conditions permitting activation of the mammalian SNORF36 receptor;
(b) determining whether the extent or amount of activation of the mammalian SNORF36 receptor is reduced in the presence of one or more of the compounds, relative to the extent or amount of activation of the mammalian SNORF36 receptor in the absence of such one or more compounds; and if so
(c) separately determining whether each such compound inhibits activation of the mammalian SNORF36 receptor for each compound included in the plurality of compounds, so as to thereby identify any compound included in such plurality of compounds which inhibits the activation of the mammalian SNORF36 receptor.

### Claim 146 (depends on 145)

A method of claim 145, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or rat SNORF36 receptor.

### Claim 147 (depends on 143, 144, 145, 146)

A method of any one of claims 143, 144, 145 or 146, wherein the cell is a mammalian cell.

### Claim 148 (depends on 147)

A method of claim 147, wherein the mammalian cell is non-neuronal in origin.

### Claim 149 (depends on 148)

The method of claim 148, wherein the non-neuronal cell is a COS-7 cell, a 293 human embryonic kidney cell, a LM(tk−) cell or an NIH-3T3 cell.

### Claim 150 (depends on 143, 144)

A composition comprising a compound identified by the method of claim 143 or 144 in an amount effective to increase mammalian SNORF36 receptor activity and a carrier.

### Claim 151 (depends on 145, 146)

A composition comprising a compound identified by the method of claim 145 or 146 in an amount effective to decrease mammalian SNORF36 receptor activity and a carrier.

### Claim 152

A method of treating an abnormality in a subject wherein the abnormality is alleviated by increasing the activity of a mammalian SNORF36 receptor which comprises. administering to the subject a compound which is a mammalian SNORF36 receptor agonist in an amount effective to treat the abnormality.

### Claim 153

A method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a mammalian SNORF36 receptor which comprises administering to the subject a compound which is a mammalian SNORF36 receptor antagonist in an amount effective to treat the abnormality.

### Claim 154 (depends on 63, 64, 82, 83, 92, 93)

A process for making a composition of matter which specifically binds to a mammalian SNORF36 receptor which comprises identifying a chemical compound using the process of any one of claims 63, 64, 82, 83, 92 or 93 and then synthesizing the chemical compound or a novel structural and functional analog or homolog thereof.

### Claim 155 (depends on 154)

The process of claims 154, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.

### Claim 156 (depends on 117, 124)

A process for making a composition of matter which specifically binds to a mammalian SNORF36 receptor which comprises identifying a chemical compound using the process of any of claims 117, 124, or 143 and then synthesizing the chemical compound or a novel structural and functional analog or homolog thereof.

### Claim 157 (depends on 156)

The process of claim 156, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.

### Claim 158 (depends on 118, 128, 145)

A process for making a composition of matter which specifically binds to a mammalian SNORF36 receptor which comprises identifying a chemical compound using the process of any of claims 118, 128 or 145 and then synthesizing the chemical compound or a novel structural and functional analog or homolog thereof.

### Claim 159 (depends on 158)

The process of claim 158, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.

### Claim 160 (depends on 63, 64, 82, 83, 92, 93)

A process for preparing a composition which comprises admixing a carrier and a pharmaceutically effective amount of a chemical compound identified by the process of any of claims 63, 64, 82, 83, 92 or 93 or a novel structural and functional analog or homolog thereof.

### Claim 161 (depends on 160)

The process of claim 160, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.

### Claim 162 (depends on 117, 124)

A process for preparing a composition which comprises admixing a carrier and a pharmaceutically effective amount of a chemical compound identified by the process of any of claims 117, 124, or 143 or a novel structural and functional analog or homolog thereof.

### Claim 163 (depends on 162)

The process of claim 162, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.

### Claim 164 (depends on 118, 128, 145)

A process for preparing a composition which comprises admixing a carrier and a pharmaceutically effective amount of a chemical compound identified by the process of any of claims 118, 128 or 145 or a novel structural and functional analog or homolog thereof.

### Claim 165 (depends on 164)

The process of claim 164, wherein the mammalian SNORF36 receptor is a human SNORF36a receptor, a human SNORF36b receptor or a rat SNORF36 receptor.
